Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    LB 102

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LB Pharma Presents NOVA-1 LB-102 Cognition Data at SIRS Society
    LB Pharma Presents NOVA-1 LB-102 Cognition Data at SIRS Society

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263952/0/en/LB-Pharmaceuticals-Presents-New-Analysis-from-the-Phase-2-NOVA-1-Trial-Highlighting-LB-102-s-Potential-Impact-on-Cognitive-Performance-at-the-2026-Annual-Congress-of-the-Schizophre.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    LB Pharma Reveals 2025 Financials, Corporate Update
    LB Pharma Reveals 2025 Financials, Corporate Update

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263403/0/en/LB-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    LB Pharma Starts Pivotal Ph 3 Trial of LB-102 in Schizophrenia
    LB Pharma Starts Pivotal Ph 3 Trial of LB-102 in Schizophrenia

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262125/0/en/LB-Pharmaceuticals-Initiates-Pivotal-Phase-3-Trial-NOVA-2-for-LB-102-in-Patients-with-Schizophrenia.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    LB Pharma Appoints R&D Biotech Exec Dr. Robert Lenz To Board
    LB Pharma Appoints R&D Biotech Exec Dr. Robert Lenz To Board

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251773/0/en/LB-Pharmaceuticals-Appoints-R-D-Biotech-Executive-Robert-Lenz-M-D-Ph-D-to-Board-of-Directors.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    LB Pharma Launches Phase 2 ILLUMINATE-1 Trial for LB-102
    LB Pharma Launches Phase 2 ILLUMINATE-1 Trial for LB-102

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225570/0/en/LB-Pharmaceuticals-Initiates-Phase-2-ILLUMINATE-1-Trial-in-Bipolar-Depression-Expanding-LB-102-Development-Program.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share
    LB Pharma Included In Russell 2000 And Russell 3000 Indices
    LB Pharma Included In Russell 2000 And Russell 3000 Indices

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202281/0/en/LB-Pharmaceuticals-Added-to-the-Russell-2000-and-Russell-3000-Indices.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.